Edgewise Therapeutics Inc (EWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2020 | |
| Cash Flows From Operating Activities | |
| Net Income | -3,185 |
| Depreciation Amortization | 40 |
| Accounts payable and accrued liabilities | 458 |
| Other Working Capital | 361 |
| Other Operating Activity | -413 |
| Operating Cash Flow | $-2,739 |
| Cash Flows From Investing Activities | |
| PPE Investments | -9 |
| Investing Cash Flow | $-9 |
| Cash Flows From Financing Activities | |
| Financing Cash Flow | $N/A |
| Beginning Cash Position | 23,653 |
| End Cash Position | 20,905 |
| Net Cash Flow | $-2,748 |
| Free Cash Flow | |
| Operating Cash Flow | -2,739 |
| Capital Expenditure | -9 |
| Free Cash Flow | -2,748 |